Canntab’s full suite of oral tablet products including a comprehensive range of both THC and CBD strengths will be made available to Levitee and their patients. Both Canntab and Levitee believe that a hard tablet delivery format will be the preferred dosage format by many of Levitee’s patients including more specifically the senior demographic and patients with several issues related to the use of Opiates and other related painkillers, who are largely interested in a product that is easy to administer and is also titratable due to the availability of multiple strengths.
On November 11, 2021, Canntab received its medical sales license from Health Canada for its Markham, Ontario facility, enabling the sale of all products directly to medical consumers. The amendment marked the final regulatory step required to launch the Company’s direct to consumer website, allowing patients across Canada with an authorized medical document to immediately order Canntab’s unique patented exact dosage tablets and caplets of THC and CBD in various strengths online. Exact dosing and ease of administration are the key elements in the Canntab offering, which specifically addresses the needs of the medical community and patients.
Larry Latowsky, Canntab’s CEO states, “we are thrilled that Levitee has partnered with us to support their patient’s treatments for pain management, addiction and general mental health. Canntab’s product offering is well suited to Levitee’s professional practitioners who want to prescribe CBD and/or THC for various therapies as part of their integrative health approach, general well-being as well as to address specific indications. Our exact dosage THC and CBD products are best suited to meet the needs of the thousands of Levitee patients across the province of Alberta and beyond. We look forward to working with Levitee to maximize positive patient outcomes with the use of medical cannabis.”
“We share a vision with Canntab to play a meaningful role in flattening the curve of the opioid crisis in Canada by tapering use of addictive painkillers through the substitution of viable alternatives, which can include cannabinoids like CBD and THC and combination thereof,” said Noha ElSayed, B.Sc.Pharm, APA, Executive Director, Levitee Clinics and Levitee Pharmacies, Alberta Region. “Notwithstanding the lack of clinical trials for product specific uses, cannabinoids have shown great promise to provide patients relief for multiple indications in which we specialize. I am eager for Canntab to begin servicing our pharmacies and clinics throughout Canada, as it will both drive additional revenue and better serve our patients.
About Canntab Therapeutics Limited
